Confluent (CFLT): Evaluating Valuation After Streaming Agents Launch Expands AI and Real-Time Data Capabilities

If you are watching Confluent (CFLT), there is something new to weigh this week. Confluent just unveiled Streaming Agents, a capability within its cloud platform built for Apache Flink. This announcement could be a meaningful step for the company’s push into enterprise AI, focusing on real-time data and automation. By directly connecting AI agents with streaming business data and enabling automation that can act, Confluent is signaling its ambition to become more than just a data backbone in the cloud. For anyone considering the stock, new technology like this might raise fresh questions about the future direction of the company’s growth story.

Looking at the bigger picture, Confluent’s share price has faced some pressure, down nearly 10% over the past year and about 33% since the start of the year. Momentum has pulled back even as the company reports double-digit annual revenue and net income growth. This new AI-focused product launch follows a period of cautious optimism after last quarter’s results. There is visible excitement about this move into agentic AI, yet the market response so far suggests investors are still assessing if or when this rollout could drive a turnaround.

So is Confluent now undervalued with increased attention on its valuation, or is the market already factoring in higher expectations for future growth as a result of this AI initiative?

Advertisement

Most Popular Narrative: 23.6% Undervalued

According to community narrative, Confluent is seen as significantly undervalued, reflecting bullish analyst outlooks about its growth prospects and future margins.

Rapid growth in real-time AI and agentic workloads is driving increased demand for enterprise-grade streaming and processing solutions. Confluent is seeing a projected 10x expansion in production AI use cases across hundreds of customers. This trend is expected to accelerate subscription and platform revenue over the medium to long term as these use cases mature and proliferate.

Is Confluent on the verge of a breakout? The most popular narrative describes a future where recurring revenue, market expansion, and margin transformation fuel a revaluation that stands apart from today's price. Want to see the numbers and one key metric that could change everything? Find out what analysts are really betting on.

Result: Fair Value of $24.69 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent customer optimization and competition from cloud providers could slow Confluent’s cloud revenue and threaten margin expansion in the coming quarters.

Find out about the key risks to this Confluent narrative.

Another View: What Does Our DCF Model Say?

For perspective, the SWS DCF model also points to Confluent being undervalued by the market. This valuation method reaches a similar conclusion but follows a very different line of reasoning. Could both approaches be correct, or will new tech trends alter the outlook?

Look into how the SWS DCF model arrives at its fair value.
CFLT Discounted Cash Flow as at Aug 2025
CFLT Discounted Cash Flow as at Aug 2025
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Confluent for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Confluent Narrative

If you think the current outlook misses something, or want to dig into the numbers yourself, you can craft your own perspective in just minutes. Do it your way

A great starting point for your Confluent research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

Don't let opportunity pass you by when there are promising stocks beyond Confluent waiting to be found. If you want to get a step ahead of the crowd, use these smart shortcuts to highlight shares with serious potential for your portfolio:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Kshitija Bhandaru

Kshitija Bhandaru

Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.

About NasdaqGS:CFLT

Confluent

Operates a data streaming platform in the United States and internationally.

Excellent balance sheet with very low risk.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
66 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0